Assessing the Protective Potential of H1N1 Influenza Virus Hemagglutinin Head and Stalk Antibodies in Humans
暂无分享,去创建一个
A. Monto | S. Hensley | J. Petrie | E. Martin | L. Lamerato | Trevor Griesman | S. Toulmin | S. R. Christensen | Sushila A. Toulmin | Shannon R. Christensen
[1] G. Pawelec. Faculty Opinions recommendation of Assessing the protective potential of H1N1 influenza virus hemagglutinin head and stalk antibodies in humans. , 2020 .
[2] M. Eichelberger,et al. Evaluation of correlates of protection against influenza A(H3N2) and A(H1N1)pdm09 infection: Applications to the hospitalized patient population , 2018, bioRxiv.
[3] R. Albrecht,et al. A Live-Attenuated Prime, Inactivated Boost Vaccination Strategy with Chimeric Hemagglutinin-Based Universal Influenza Virus Vaccines Provides Protection in Ferrets: A Confirmatory Study , 2018, Vaccines.
[4] J. Wrammert,et al. Broadly Reactive Human Monoclonal Antibodies Elicited following Pandemic H1N1 Influenza Virus Exposure Protect Mice against Highly Pathogenic H5N1 Challenge. , 2018 .
[5] D. Weissman,et al. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses , 2018, The Journal of experimental medicine.
[6] J. Taubenberger,et al. Evaluation of Preexisting Anti-Hemagglutinin Stalk Antibody as a Correlate of Protection in a Healthy Volunteer Challenge with Influenza A/H1N1pdm Virus , 2018, mBio.
[7] T. Ross,et al. Towards a universal influenza vaccine: different approaches for one goal , 2018, Virology Journal.
[8] Seth J. Zost,et al. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains , 2017, Proceedings of the National Academy of Sciences.
[9] K. Subbarao,et al. In Vitro Neutralization Is Not Predictive of Prophylactic Efficacy of Broadly Neutralizing Monoclonal Antibodies CR6261 and CR9114 against Lethal H2 Influenza Virus Challenge in Mice , 2017, Journal of Virology.
[10] Catharine I Paules,et al. The Pathway to a Universal Influenza Vaccine. , 2017, Immunity.
[11] P. Palese,et al. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for In Vivo Protection in a Serum Transfer Mouse Challenge Model , 2017, mBio.
[12] F. Krammer,et al. Universal influenza virus vaccines and therapeutic antibodies. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[13] M. Kiso,et al. A Broadly Reactive Human Anti-hemagglutinin Stem Monoclonal Antibody That Inhibits Influenza A Virus Particle Release , 2017, EBioMedicine.
[14] Matthew Angel,et al. Defining B Cell Immunodominance to Viruses , 2017, Nature Immunology.
[15] Caitlin E. Mullarkey,et al. Broadly Neutralizing Hemagglutinin Stalk-Specific Antibodies Induce Potent Phagocytosis of Immune Complexes by Neutrophils in an Fc-Dependent Manner , 2016, mBio.
[16] W. Marasco,et al. A broadly neutralizing anti-influenza antibody reveals ongoing capacity of haemagglutinin-specific memory B cells to evolve , 2016, Nature Communications.
[17] A. Wilder-Smith,et al. Randomized controlled trials for influenza drugs and vaccines: a review of controlled human infection studies. , 2016, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[18] P. Palese,et al. Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans , 2016, mBio.
[19] R. Webby,et al. The Hemagglutinin Stem-Binding Monoclonal Antibody VIS410 Controls Influenza Virus-Induced Acute Respiratory Distress Syndrome , 2016, Antimicrobial Agents and Chemotherapy.
[20] P. Wilson,et al. Germinal Center Selection and the Antibody Response to Influenza , 2015, Cell.
[21] A. Monto,et al. Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection. , 2015, The Journal of infectious diseases.
[22] Adrian Apetri,et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen , 2015, Science.
[23] J. Mascola,et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection , 2015, Nature Medicine.
[24] Brantley R. Herrin,et al. Lamprey VLRB response to influenza virus supports universal rules of immunogenicity and antigenicity , 2015, eLife.
[25] Brantley R. Herrin,et al. Author response: Lamprey VLRB response to influenza virus supports universal rules of immunogenicity and antigenicity , 2015 .
[26] F. Hayden,et al. Design, recruitment, and microbiological considerations in human challenge studies. , 2015, The Lancet. Infectious diseases.
[27] Florian Krammer,et al. Advances in the development of influenza virus vaccines , 2015, Nature Reviews Drug Discovery.
[28] R. Davey,et al. Validation of the wild-type influenza A human challenge model H1N1pdMIST: an A(H1N1)pdm09 dose-finding investigational new drug study. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[29] P. Palese,et al. Advances in the development of influenza virus vaccines , 2015, Nature Reviews Drug Discovery.
[30] S. de Lusignan,et al. Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 mid-season results. , 2015, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[31] D. Skowronski,et al. Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada's Sentinel Physician Surveillance Network, January 2015. , 2015, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[32] Caitlin E. Mullarkey,et al. Broadly Neutralizing Anti-Influenza Virus Antibodies: Enhancement of Neutralizing Potency in Polyclonal Mixtures and IgA Backbones , 2015, Journal of Virology.
[33] Gillian Dekkers,et al. IgG Subclasses and Allotypes: From Structure to Effector Functions , 2014, Front. Immunol..
[34] J. Bloom,et al. Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013–2014 influenza season , 2014, Proceedings of the National Academy of Sciences.
[35] I. Wilson,et al. Characterization of a Broadly Neutralizing Monoclonal Antibody That Targets the Fusion Domain of Group 2 Influenza A Virus Hemagglutinin , 2014, Journal of Virology.
[36] R. Cox,et al. Serum IgG titres, but not avidity, correlates with neutralizing antibody response after H5N1 vaccination. , 2014, Vaccine.
[37] T. Ross,et al. Eliciting broadly protective antibody responses against influenza. , 2014, Current opinion in immunology.
[38] A. Takada,et al. Comparison of Antiviral Activity between IgA and IgG Specific to Influenza Virus Hemagglutinin: Increased Potential of IgA for Heterosubtypic Immunity , 2014, PloS one.
[39] P. Palese,et al. Broadly neutralizing hemagglutinin stalk–specific antibodies require FcγR interactions for protection against influenza virus in vivo , 2014, Nature Medicine.
[40] Matthew S. Miller,et al. Assessment of Influenza Virus Hemagglutinin Stalk-Based Immunity in Ferrets , 2014, Journal of Virology.
[41] Antoine M. van Oijen,et al. Mechanisms of Hemagglutinin Targeted Influenza Virus Neutralization , 2013, PloS one.
[42] P. Palese,et al. Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system. , 2013, Journal of visualized experiments : JoVE.
[43] Florian Krammer,et al. Influenza virus hemagglutinin stalk-based antibodies and vaccines. , 2013, Current opinion in virology.
[44] R. Lamb,et al. Textbook of Influenza , 2013 .
[45] Nicole M. Bouvier,et al. Recombinant IgA Is Sufficient To Prevent Influenza Virus Transmission in Guinea Pigs , 2013, Journal of Virology.
[46] John J. Treanor,et al. H3N2 Influenza Virus Infection Induces Broadly Reactive Hemagglutinin Stalk Antibodies in Humans and Mice , 2013, Journal of Virology.
[47] N. S. Laursen,et al. Highly Conserved Protective Epitopes on Influenza B Viruses , 2012, Science.
[48] J. Ravetch,et al. Mouse model recapitulating human Fcγ receptor structural and functional diversity , 2012, Proceedings of the National Academy of Sciences.
[49] A. Jegerlehner,et al. Universal vaccine against influenza virus: Linking TLR signaling to anti‐viral protection , 2012, European journal of immunology.
[50] R. Albrecht,et al. Influenza Viruses Expressing Chimeric Hemagglutinins: Globular Head and Stalk Domains Derived from Different Subtypes , 2012, Journal of Virology.
[51] J. Oxford,et al. Use of a human influenza challenge model to assess person-to-person transmission: proof-of-concept study. , 2011, The Journal of infectious diseases.
[52] J. Skehel,et al. A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins , 2011, Science.
[53] Martin H. Koldijk,et al. A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses , 2011, Science.
[54] J. Yewdell,et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection , 2011, The Journal of experimental medicine.
[55] David Baltimore,et al. Permissive Secondary Mutations Enable the Evolution of Influenza Oseltamivir Resistance , 2010, Science.
[56] K. Subbarao,et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. , 2010, The Journal of clinical investigation.
[57] John Steel,et al. Influenza Virus Vaccine Based on the Conserved Hemagglutinin Stalk Domain , 2010, mBio.
[58] R. Hai,et al. Broadly Protective Monoclonal Antibodies against H3 Influenza Viruses following Sequential Immunization with Different Hemagglutinins , 2010, PLoS pathogens.
[59] Gira Bhabha,et al. Antibody Recognition of a Highly Conserved Influenza Virus Epitope , 2009, Science.
[60] Boguslaw Stec,et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses , 2009, Nature Structural &Molecular Biology.
[61] Y. Guan,et al. Heterosubtypic Neutralizing Monoclonal Antibodies Cross-Protective against H5N1 and H1N1 Recovered from Human IgM+ Memory B Cells , 2008, PloS one.
[62] Jessica M Malenfant,et al. CD107a as a functional marker for the identification of natural killer cell activity. , 2004, Journal of immunological methods.
[63] Niall Johnson,et al. Updating the Accounts: Global Mortality of the 1918-1920 "Spanish" Influenza Pandemic , 2002, Bulletin of the history of medicine.
[64] R. Webster,et al. A DNA transfection system for generation of influenza A virus from eight plasmids. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[65] J. Yewdell,et al. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype) , 1982, Cell.
[66] R. Webster,et al. Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies , 1981, Nature.
[67] A. S. Beare,et al. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses , 1972, Epidemiology and Infection.
[68] T. Francis. DISSOCIATION OF HEMAGGLUTINATING AND ANTIBODY-MEASURING CAPACITIES OF INFLUENZA VIRUS , 1946, The Journal of experimental medicine.
[69] G. K. Hirst. THE QUANTITATIVE DETERMINATION OF INFLUENZA VIRUS AND ANTIBODIES BY MEANS OF RED CELL AGGLUTINATION , 1942, The Journal of experimental medicine.
[70] S. de Lusignan,et al. Low effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 mid-season results. , 2015, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.